Agitation clinical trials at UCLA

1 research study open to eligible people

Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
open to eligible people ages 50-90
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Los Angeles, California and other locations

Last updated: August 13, 2024